Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Inducible T-bet deletion reveals tissue-specific requirements in NKp46+ ILC immunobiology and response to murine cytomegalovirus.

Nature communications·2026

Same author

Pumping up immunity: exercise flexes memory NK cell attack.

Blood advances·2026

Same author

Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.

Cancer immunology research·2026

Same author

NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma.

Journal of immunology (Baltimore, Md. : 1950)·2025

Same author

Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: Aug 20, 2025

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Allogeneic natural killer cell therapy.

Melissa M Berrien-Elliott¹, Miriam T Jacobs¹, Todd A Fehniger¹

¹Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.

|November 23, 2022

Summary

This summary is machine-generated.

Natural killer (NK) cells offer a promising alternative to CAR T-cell therapy for cancer treatment. These allogeneic cells are readily available, safer, and more cost-effective, paving the way for next-generation cellular therapies.

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Experiment Videos

Last Updated: Aug 20, 2025

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Area of Science:

Immunology and Cellular Therapy
Oncology
Biotechnology

Background:

Current adoptive cell therapies, like chimeric antigen receptor (CAR) T-cell therapy, face limitations including lengthy production times, high costs, and potential toxicities.
CAR T-cell therapy is associated with adverse effects such as cytokine release syndrome and neurotoxicity, limiting its widespread application.

Approach:

Natural killer (NK) cells are being investigated as an alternative allogeneic cell source for cancer immunotherapy due to their inherent anti-cancer properties.
NK cells can be manufactured at scale, cryopreserved, and are available off-the-shelf, overcoming the logistical challenges of autologous therapies.
Advances in NK cell biology and genetic engineering are enabling strategies to enhance their efficacy and persistence in vivo.

Key Points:

NK cells possess natural cancer-recognition abilities and mediate immune functions without inducing graft-versus-host disease or severe toxicities like CRS and ICANS.
Allogeneic NK cell products are progressing through clinical trials with encouraging initial outcomes.
Engineering strategies focus on overcoming NK cell inhibition, improving target recognition, and enhancing functional persistence.

Conclusions:

NK cell-based therapies represent a significant advancement towards developing potent, off-the-shelf cellular treatments for hematological malignancies.
The development of allogeneic NK cell therapies promises to overcome the manufacturing and toxicity challenges associated with current CAR T-cell treatments.